ALFA Finder| Management target | Revenue 12.0% FY27 |
|---|
| Revenue growth | 2% YoY growth; sequentially down 7% due to revenue reversal. |
|---|---|
| Margins | EBITDA margin contracted to 27% from 30% YoY; energy costs blamed. |
| Demand visibility | Strong pipeline noted; US B2C improving while US B2B shifts. |
| Management confidence | Balanced, attributing current softness to accounting timing and macro factors. |
Growth
Revenue grew 2% YoY to ₹189.8 Cr, while EBITDA fell 10% YoY. Growth was led by specialized manufacturing.
Outlook
Management anticipates double-digit revenue growth and 30-32% EBITDA margins for the full FY27 period.
Risks
US B2B business remains stagnant due to geopolitical tension and slow shifts to branded business models.
Last quarter's promises, checked
Delivered
- Guided double-digit growth for FY26 → delivered 17% growth (= BEAT)
- Guided 30-32% EBITDA margin for FY26 → delivered 31% (= BEAT)
- Guided PAT growth for FY26 → delivered 30% YoY growth (= BEAT)
Partly delivered
- Guided new R&D center operational by H2FY27 → ongoing capex of ₹123 Cr (= PARTIAL)
- Guided US market growth → US B2B remains stagnant/challenging (= PARTIAL)
Missed
- Guided steady momentum into FY27 → delivered 2% YoY revenue growth (= MISS)
- Guided steady margins for Q1FY27 → delivered 27% vs 31% previous (= MISS)
Earnings Call Transcript filed with BSE, NSE: ADVENZYMES. Summary written with AI assistance from the document.
Advanced Enzyme Technologies Ltd: key numbers
- Share price
- ₹283.85
- Market cap
- ₹3,178 Cr
- Revenue (annual)
- ₹745.8 Cr
- Net profit (annual)
- ₹168.7 Cr
- P/E (TTM)
- 18.6×Sector 43.8×
- Promoter holding
- 43.56%+0.32% QoQ
- FII holding
- 26.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Advanced Enzyme Technologies Ltd
All →Advanced Enzyme Technologies Earnings Call Transcript: Key Takeaways
Clean headline: revenue +16% YoY, EBITDA 34%, PAT +14%. Growth leans on deferred sales and rising top-10 customer concentration (46%). US recovery is only hoped for.
Advanced Enzyme Technologies Promoter Reclassification
Advanced Enzyme Technologies applied to exchanges to reclassify 13 promoter group members as public under Regulation 31A. They hold 59,000 shares combined, about 0.05%.
Advanced Enzyme Technologies Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹2,145mn (+16% YoY), EBITDA ₹721mn (+20%, 34% margin), PAT ₹512mn (+14%). H1 revenue +10%, PAT +5%. Industrial bio-processing and animal nutrition lead growth.
Advanced Enzyme Technologies Results Update
Advanced Enzyme Technologies issued a press release highlighting unaudited Q2 and half-year FY27 results. Revenue and profit grew year-on-year, with EBITDA and PAT margins reported.
Advanced Enzyme Technologies Q2 FY27 Results: Net Profit ₹51.2 Cr, Up 14.5% YoY
Advanced Enzyme Technologies Ltd reported revenue from operations of ₹214.5 Cr (+16.3% YoY) and net profit of ₹51.2 Cr (+14.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.2 Cr · +14.5% YoY
Advanced Enzyme Technologies Capital Structure Change
Advanced Enzyme closed its buyback after purchasing 2,410,906 shares for ₹69.70 Crore. Closure took effect October 30, 2026, ahead of the scheduled period.
- Value
- ₹69.70 Cr
- Execution
- August 14, 2026 to October 30, 2026